MDR TB is tuberculosis caused by strains of Mycobacterium tuberculosis that are resistant to both isoniazid and rifampicin, the most potent anti-TB drugs. In India in 2012, MDR TB accounted for approximately 2.2% of new TB cases and 15% of retreatment cases. Diagnosis requires culture and drug susceptibility testing showing resistance to both isoniazid and rifampicin. Treatment follows WHO DOTS Plus guidelines and involves a regimen of several second-line drugs for 20 months or longer. Adherence to treatment is critical for successful treatment of MDR TB.